New Zealand markets open in 6 hours 56 minutes

OCGN Jan 2023 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.7700-0.1300 (-14.44%)
As of 10:33AM EDT. Market open.
Full screen
Loading interactive chart…
  • Motley Fool

    Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript

    Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.

  • GlobeNewswire

    Ocugen Provides Business Update & Second Quarter 2022 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Dosing patients in U.S. Phase 2/3 COVAXIN™ (BBV152) clinical trialCompleted dosing of patients in Cohort 1 of OCU400 gene therapy product candidateExpanding product pipeline with the regenerative medicine cell therapy program NeoCart® MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and

  • Zacks

    Ocugen Q2 Preview: Rebound Quarter Inbound?

    Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.